^
Association details:
| Biomarker: | DNMT3A mutation + NPM1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | RVU120 (CDK19 inhibitor, CDK8 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PRECLINICAL AND CLINICAL SIGNS OF RVU120 EFFICACY, A SPECIFIC CDK8/19 INHIBITOR IN DNMT3A MUTATION POSITIVE AML AND HR-MDS
Published date:
05/12/2022
Excerpt:
...13 patients have been enrolled into CLI120-001 trial, including 2 patients with DNMT3A mutations. Notably, first R/R AML patient that achieved CR was positive for DNMT3A and NPM1 mutations….Preliminary evidence of clinical response to RVU120 has been also shown in R/R AML and HR-MDS patients positive for DNMT3A mutations.
